RNA m6A methylation regulators in liver cancer.

Qiaoping Xu, Ning Ren, Lanqi Ren, Yibei Yang, Junjie Pan, Hongkai Shang
Author Information
  1. Qiaoping Xu: Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Westlake University School of Medicine, Hangzhou, 310006, China.
  2. Ning Ren: Fourth Clinical Medical College of Zhejiang, Chinese Medical University, Hangzhou, 310051, Zhejiang, China.
  3. Lanqi Ren: Fourth Clinical Medical College of Zhejiang, Chinese Medical University, Hangzhou, 310051, Zhejiang, China.
  4. Yibei Yang: Fourth Clinical Medical College of Zhejiang, Chinese Medical University, Hangzhou, 310051, Zhejiang, China.
  5. Junjie Pan: Fourth Clinical Medical College of Zhejiang, Chinese Medical University, Hangzhou, 310051, Zhejiang, China.
  6. Hongkai Shang: Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Westlake University School of Medicine, Hangzhou, 310006, China. hongkaishang@zju.edu.cn.

Abstract

Liver cancer is one of the most common cancers in the world and a primary cause of cancer-related death. In recent years, despite the great development of diagnostic methods and targeted therapies for liver cancer, the incidence and mortality of liver cancer are still on the rise. As a universal post-transcriptional modification, N6-methyladenosine (m6A) modification accomplishes a dynamic and reversible m6A modification process, which is executed by three types of regulators, methyltransferases (called writers), demethylases (called erasers) and m6A-binding proteins (called readers). Many studies have shown that m6A RNA methylation has an important impact on RNA metabolism, whereas its regulation exception is bound up with the occurrence of human malignant tumors. Aberrant methylation of m6A RNA and the expression of related regulatory factors may be of the essence in the pathogenesis and progression of liver cancer, yet the precise molecular mechanism remains unclear. In this paper, we review the current research situations of m6A methylation in liver cancer. Among the rest, we detail the mechanism by which methyltransferases, demethylases and m6A binding proteins regulate the occurrence and development of liver cancer by modifying mRNA. As well as the potential effect of m6A regulators in hepatocarcinogenesis and progression. New ideas and approaches will be given to the prevention and treatment of liver cancer through the following relevant research results.

References

  1. Aging (Albany NY). 2021 Nov 8;13(21):24205-24218 [PMID: 34747720]
  2. Mol Cancer. 2020 Feb 27;19(1):40 [PMID: 32106857]
  3. Genes (Basel). 2022 Apr 11;13(4): [PMID: 35456475]
  4. Cell Commun Signal. 2018 Aug 24;16(1):50 [PMID: 30143009]
  5. Elife. 2021 Nov 15;10: [PMID: 34779401]
  6. Transl Oncol. 2022 Feb;16:101308 [PMID: 34911015]
  7. Cell Death Dis. 2020 Sep 11;11(9):741 [PMID: 32917856]
  8. Front Oncol. 2021 Apr 13;11:635329 [PMID: 33928028]
  9. Crit Rev Biotechnol. 2020 Aug;40(5):639-652 [PMID: 32321323]
  10. Mol Cancer. 2022 Jul 20;21(1):149 [PMID: 35858900]
  11. Oncogene. 2020 Jun;39(23):4507-4518 [PMID: 32366907]
  12. Front Cell Dev Biol. 2020 Aug 11;8:741 [PMID: 32850851]
  13. Exp Hematol Oncol. 2022 Aug 9;11(1):45 [PMID: 35945641]
  14. Ann Hepatobiliary Pancreat Surg. 2018 Nov;22(4):305-309 [PMID: 30588520]
  15. ESMO Open. 2016 Mar 17;1(2):e000042 [PMID: 27843598]
  16. Oncogene. 2019 May;38(21):4182-4196 [PMID: 30936459]
  17. Biomarkers. 2020 Sep;25(6):436-440 [PMID: 32662667]
  18. Front Mol Biosci. 2020 Dec 02;7:577460 [PMID: 33344502]
  19. Pathol Res Pract. 2021 Mar;219:153369 [PMID: 33626406]
  20. Aliment Pharmacol Ther. 2010 Feb 15;31(4):461-76 [PMID: 19925500]
  21. Mol Biotechnol. 2019 May;61(5):355-364 [PMID: 30637606]
  22. Biochim Biophys Acta Gene Regul Mech. 2019 Mar;1862(3):329-342 [PMID: 30660758]
  23. Int J Radiat Oncol Biol Phys. 2021 Oct 1;111(2):491-501 [PMID: 34044094]
  24. Genomics Proteomics Bioinformatics. 2018 Apr;16(2):99-107 [PMID: 29715522]
  25. Front Genet. 2022 Sep 06;13:1007696 [PMID: 36171885]
  26. Mol Ther Nucleic Acids. 2021 Jan 01;23:887-896 [PMID: 33614237]
  27. Nat Cell Biol. 2022 Feb;24(2):205-216 [PMID: 35145225]
  28. Front Cell Dev Biol. 2022 Feb 03;10:813581 [PMID: 35186927]
  29. Biomolecules. 2020 Jul 17;10(7): [PMID: 32709063]
  30. Hum Pathol. 2021 Jul;113:39-46 [PMID: 33905775]
  31. Cell Biol Int. 2021 Feb;45(2):334-344 [PMID: 33079435]
  32. Int J Clin Exp Pathol. 2019 Sep 01;12(9):3376-3383 [PMID: 31934180]
  33. Mol Metab. 2020 Dec;42:101085 [PMID: 32956847]
  34. J Biol Chem. 2021 Aug;297(2):100973 [PMID: 34280435]
  35. Recent Results Cancer Res. 2016;208:177-198 [PMID: 27909908]
  36. Hepatology. 2020 Dec;72(6):2029-2050 [PMID: 32154934]
  37. Front Cell Dev Biol. 2021 Feb 18;9:627706 [PMID: 33681207]
  38. Front Oncol. 2022 Aug 03;12:916583 [PMID: 35992793]
  39. Nat Rev Genet. 2014 May;15(5):293-306 [PMID: 24662220]
  40. Cancer Cell Int. 2022 Jan 7;22(1):11 [PMID: 34996469]
  41. Front Immunol. 2022 Apr 04;13:849592 [PMID: 35444654]
  42. Mol Cancer. 2020 May 12;19(1):88 [PMID: 32398132]
  43. Ann Med. 2022 Dec;54(1):2785-2795 [PMID: 36370068]
  44. Int J Mol Sci. 2021 Feb 02;22(3): [PMID: 33540684]
  45. Exp Hematol Oncol. 2021 Jun 4;10(1):35 [PMID: 34088349]
  46. BMC Cancer. 2021 Jun 10;21(1):686 [PMID: 34112124]
  47. J Cancer Res Clin Oncol. 2019 Jan;145(1):19-29 [PMID: 30465076]
  48. Arch Toxicol. 2021 May;95(5):1621-1629 [PMID: 33713148]
  49. Oncol Lett. 2021 Jul;22(1):538 [PMID: 34084217]
  50. Clin Transl Oncol. 2023 Jan;25(1):269-282 [PMID: 36163443]
  51. Discov Oncol. 2022 Nov 25;13(1):131 [PMID: 36434140]
  52. J Hepatocell Carcinoma. 2022 Nov 02;9:1149-1169 [PMID: 36349146]
  53. Nucleic Acids Res. 2017 Jun 2;45(10):6051-6063 [PMID: 28334903]
  54. Pathol Oncol Res. 2020 Jul;26(3):1615-1623 [PMID: 31506804]
  55. Int J Biol Sci. 2022 Jul 4;18(11):4432-4451 [PMID: 35864970]
  56. Front Oncol. 2021 Apr 15;11:611544 [PMID: 33937023]
  57. Cancers (Basel). 2020 Dec 25;13(1): [PMID: 33375621]
  58. J Cell Mol Med. 2022 May;26(9):2505-2519 [PMID: 35348293]
  59. Nat Rev Gastroenterol Hepatol. 2013 Jan;10(1):34-42 [PMID: 23147664]
  60. Hepatology. 2018 Jun;67(6):2254-2270 [PMID: 29171881]
  61. Front Pharmacol. 2022 Jun 16;13:933332 [PMID: 35784761]
  62. Redox Biol. 2022 Aug;54:102378 [PMID: 35779442]
  63. Cancer Lett. 2019 Feb 1;442:252-261 [PMID: 30423408]
  64. Biomark Res. 2022 Aug 16;10(1):59 [PMID: 35971182]
  65. Mol Cancer. 2022 Mar 16;21(1):76 [PMID: 35296338]
  66. Cell. 2015 Sep 10;162(6):1299-308 [PMID: 26321680]
  67. Mol Cancer. 2019 Nov 18;18(1):163 [PMID: 31735169]
  68. Int J Biol Sci. 2022 Aug 1;18(13):5001-5018 [PMID: 35982895]
  69. Int J Biol Sci. 2020 Apr 15;16(11):1929-1940 [PMID: 32398960]
  70. Int J Clin Exp Pathol. 2018 Mar 01;11(3):1175-1185 [PMID: 31938212]
  71. J Prev Med Hyg. 2020 Jul 04;61(2):E259-E289 [PMID: 32803012]
  72. Int J Mol Sci. 2022 Aug 09;23(16): [PMID: 36012108]
  73. J Hepatol. 2019 Sep;71(3):543-552 [PMID: 31176752]
  74. Clin Liver Dis. 2020 Nov;24(4):591-610 [PMID: 33012447]
  75. Aging (Albany NY). 2020 Nov 6;12(21):21638-21659 [PMID: 33159022]
  76. Nucleic Acids Res. 2019 Jan 10;47(1):375-390 [PMID: 30371874]
  77. Leukemia. 2020 May;34(5):1354-1363 [PMID: 31768017]
  78. Cancer Cell Int. 2020 Jul 29;20:353 [PMID: 32760220]
  79. Biochim Biophys Acta Rev Cancer. 2022 Mar;1877(2):188691 [PMID: 35122883]
  80. Mol Cancer. 2020 Aug 10;19(1):123 [PMID: 32772918]
  81. Semin Cancer Biol. 2021 Oct;75:97-115 [PMID: 33220459]
  82. Cancer Cell Int. 2020 Jul 28;20:347 [PMID: 32742194]
  83. Front Cell Dev Biol. 2022 Nov 07;10:973548 [PMID: 36420139]
  84. Mol Cancer. 2019 Aug 22;18(1):127 [PMID: 31438961]
  85. Onco Targets Ther. 2019 May 07;12:3421-3428 [PMID: 31118692]
  86. Cell Death Dis. 2022 Jan 21;13(1):72 [PMID: 35064107]
  87. Cancer Lett. 2019 May 28;450:98-109 [PMID: 30790682]
  88. J Clin Lab Anal. 2021 Sep;35(9):e23931 [PMID: 34398984]
  89. Cell Commun Signal. 2022 Sep 9;20(1):140 [PMID: 36085064]
  90. Mol Cancer. 2020 Feb 28;19(1):44 [PMID: 32111216]
  91. Front Oncol. 2020 Jul 21;10:900 [PMID: 32850303]
  92. Clin Res Hepatol Gastroenterol. 2021 May;45(3):101664 [PMID: 33667731]
  93. Transcription. 2021 Oct;12(5):266-276 [PMID: 35380917]
  94. Oncol Lett. 2020 Aug;20(2):1409-1417 [PMID: 32724383]
  95. Open Biol. 2020 Sep;10(9):200091 [PMID: 32898471]
  96. Cancer Cell. 2020 Jul 13;38(1):79-96.e11 [PMID: 32531268]
  97. Cell Prolif. 2022 Jan;55(1):e13157 [PMID: 34821414]
  98. Stem Cells Dev. 2021 Nov;30(22):1115-1125 [PMID: 34514861]
  99. Cell Death Dis. 2022 Nov 5;13(11):926 [PMID: 36335087]
  100. Cell Immunol. 2021 Mar;361:104295 [PMID: 33508529]
  101. Gastroenterology. 2017 Mar;152(4):745-761 [PMID: 28043904]
  102. World J Clin Cases. 2022 Sep 16;10(26):9545-9549 [PMID: 36159415]
  103. Int J Gen Med. 2021 Oct 29;14:7411-7422 [PMID: 34744452]
  104. J Oncol. 2021 Nov 23;2021:6461552 [PMID: 34858499]
  105. Cancer Lett. 2021 Oct 10;518:256-265 [PMID: 34339799]
  106. Gene. 2021 Oct 20;800:145834 [PMID: 34274483]
  107. J Hematol Oncol. 2022 Jan 21;15(1):8 [PMID: 35063010]
  108. Transl Cancer Res. 2020 Jan;9(1):323-334 [PMID: 35117186]
  109. Cancer Cell Int. 2022 Nov 15;22(1):353 [PMID: 36376862]
  110. Aging (Albany NY). 2022 Mar 12;14(5):2304-2319 [PMID: 35278064]
  111. Wiley Interdiscip Rev RNA. 2013 Jul-Aug;4(4):397-422 [PMID: 23681756]
  112. Oncol Lett. 2021 Nov;22(5):775 [PMID: 34589154]
  113. Nat Commun. 2020 Apr 3;11(1):1685 [PMID: 32245947]
  114. Int J Mol Sci. 2022 Mar 30;23(7): [PMID: 35409166]
  115. Dig Dis Sci. 2021 Apr;66(4):1110-1126 [PMID: 32333311]
  116. Cell Biosci. 2022 May 7;12(1):55 [PMID: 35526051]

Grants

  1. 2020E10021/Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province
  2. 2018ZQ036/Scientific Research Foundation of Zhejiang Province Traditional Chinese Medical Administration Bureau

Word Cloud

Created with Highcharts 10.0.0cancerm6AliverRNAmethylationmodificationregulatorscalleddevelopmentmethyltransferasesdemethylasesproteinsoccurrenceprogressionmechanismresearchLiveronecommoncancersworldprimarycausecancer-relateddeathrecentyearsdespitegreatdiagnosticmethodstargetedtherapiesincidencemortalitystillriseuniversalpost-transcriptionalN6-methyladenosineaccomplishesdynamicreversibleprocessexecutedthreetypeswriterserasersm6A-bindingreadersManystudiesshownimportantimpactmetabolismwhereasregulationexceptionboundhumanmalignanttumorsAberrantexpressionrelatedregulatoryfactorsmayessencepathogenesisyetprecisemolecularremainsunclearpaperreviewcurrentsituationsAmongrestdetailbindingregulatemodifyingmRNAwellpotentialeffecthepatocarcinogenesisNewideasapproacheswillgivenpreventiontreatmentfollowingrelevantresults

Similar Articles

Cited By